An interventional study of Resveratrol and Placebo in Coronary Artery Disease, Menopause and Endothelial Dysfunction, sponsored by InCor Heart Institute. Recruiting at 1 site in Brazil. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-04-11.
Sponsored by InCor Heart Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 29 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 70th largest by planned enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2023, is one of 67 with no phase, reaches primary completion later than 5 of the 28 other live ones, and was the 128th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:
Scitech Produtos Medicos SA · Sites in Brazil
Ages 18+
InCor Heart Institute · Sites in Brazil
Ages 45–70 · Women only
University of Sao Paulo General Hospital · Sites in Brazil
Ages 46–69 · Men only
Instituto Nacional de Cardiologia de Laranjeiras · Sites in Brazil
Ages 40–70 · Healthy volunteers
University of Sao Paulo General Hospital · Sites in Brazil
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 55 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 25 · Phase 4 17
First in 1999; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 123 interventional studies, 740 across the 28 observational. Of the 93 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 152 have an industry lead sponsor. The 10 most frequent:
InCor Heart Institute is the lead sponsor of 27 studies on the registry; 4 are open to participants now.
InCor Heart Institute has 6 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Artery Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579807Instituto Nacional de Cardiologia de LaranjeirasCardiac Rehabilitation and Coronary Artery Disease | 2026-12-31 |
| NCT07699679Federal University of São PauloPhotobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting. | 2027-08 |
| NCT07734831University of the State of Santa CatarinaTELEREHAB-BR: Cardiovascular Rehabilitation Models Trial | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiovascular diseases (CVD) and neoplasms are the main causes of death in Brazilian women. Coronary artery disease (CAD) and stroke were responsible for approximately 54% of deaths from CVD in this population. In Brazil, cancers were the second cause of death and in 2017 were responsible for 58% of deaths in women. CVD and cancer share some risk factors, and control of these factors is associated with a significant reduction in cancer incidence. These two causes of death, although apparently disparate, share similar lifestyles and health risk factors, suggesting some common pathways and basic molecular networks. In women, the presence of estrogen has protective effects against atherosclerosis and, with the decline in hormone production at menopause, the incidence and prevalence of CAD increase substantially. Although the estrogen pathway is supposed to have a central effect on this increased risk, it is still debated whether other non-estrogenic mechanisms are related, since hormone replacement alone does not reduce cardiovascular events. Sirtuins and soluble advanced glycation product receptors (sRAGE) are associated with increased vascular protection, while the role of apoptosis inhibiting proteins, a pathway linked to increased cancer incidence, is still unclear in the context of atherosclerosis. Resveratrol is a key activator of sirtuins and potentially modulates these metabolic pathways, reducing cardiovascular risk. This randomized, double-blind, parallel, placebo-controlled clinical trial will be carried out in 80 postmenopausal women with CAD to analyze the effect of treatment with resveratrol on serum concentration and gene expression of sirtuins-1 -3, in the serum sRAGE concentration and in the gene expression of apoptosis inhibitory proteins.
The objective of the study is to evaluate the influence of sirtuins stimulation by resveratrol on inhibitors of apoptosis proteins gene expression of circulation angiogenic cells of postmenopausal women with stable coronary artery disease.
A randomized, double-blind, parallel, placebo-controlled clinical trial in postmenopausal women with CAD submitted to 90 days of daily resveratrol supplementation days of daily supplementation with 1000 mg of resveratrol. Eighty women aged ≥55 years, with overweight or obesity grade 1 (BMI between 25 and 35 kg/m2) will be selected. The participants will be randomized into two groups, control (CON) and resveratrol (RES). After the screening, the participants will undergo the first clinical and laboratory evaluation including lipid and glucose metabolism, inflammatory biomarkers, serum concentrations and gene expression of sirtuin-1 and sirtuin-3 and soluble receptor of advanced glycation end products, and the gene expression of inhibitors of apoptosis proteins.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trans-resveratrol, 1000mg daily for 90 days.
Dietary Supplement: Resveratrol
Starch, 1000mg daily for 90 days.
Dietary Supplement: Placebo
Trans-resveratrol, 1000 mg daily for 90 days
Starch, 1000 mg daily for 90 days
Sirtuin-1 and sirtuin-3
Serum concentrations and gene expression
Time frame: 90 days
Inhibitors of apoptosis proteins
Gene expression of Bcl-2, XIAP, c-IAP1, and survivin
Time frame: 90 days
sRAGE
Serum concentrations and gene expression
Time frame: 90 days
Inflammation
Serum concentrations of proinflammatory cytokines
Time frame: 90 days
Cardiometabolic risk factors
Lipid and glucometabolic profiles
Time frame: 90 days
Anthropometric measures
BMI, skinfold thickness, and body composition
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Jun 2025, 26 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 26 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resveratrol
InCor Heart Institute